The molecular cancer diagnostics company, Agendia, has introduced ColoPrint microarray-based 18-gene expression assay.
The ColoPrint assay is designed for predicting the risk of distant recurrence for stage II colon cancer patients who have undergone surgery.
ColoPrint also helps in eliminating the gray area of indeterminate results found in 70% of patients, using clinical and pathologic factors such as T4-stage and Microsatellite Instability status.
The company said ColoPrint in combination with clinical factors, individualizes the relapse risk assessment for colon cancer patients.
Agendia CEO David Macdonald said, "ColoPrint's definitive results (either high or low risk with no in between) will enable doctors to choose treatment plans for colon cancer patients that are customized for each patient's individual needs."
